Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Kettermann

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|April 19, 2022
Informatics in Medical Product Regulation: The Right Drug at the Right Dose for the Right PatientEileen Navarro Almario, Anna Kettermann, Vaishali Popat
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 9, 2014
Biomarkers of exposure among U.S. cigar smokers: an analysis of 1999-2012 National Health and Nutrition Examination Survey (NHANES) dataJiping Chen, Anna Kettermann, Brian L Rostron, et al.
Pharmaceutical Statistics|October 30, 2024
Optimizing Sample Size Determinations for Phase 3 Clinical Trials in Type 2 DiabetesAlexander C Cambon, James Travis, Liping Sun, et al.
Urology|November 10, 2007
Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curabilityH Ballentine Carter, Anna Kettermann, Luigi Ferrucci, et al.
European Urology|November 4, 2009
The Optimal Application of Prostate-Specific Antigen (PSA) Velocity to Predict High-Risk DiseaseStacy Loeb, Anna Kettermann, Luigi Ferrucci, et al.
European Urology|July 11, 2008
PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of AgingStacy Loeb, Anna Kettermann, Luigi Ferrucci, et al.
BJU International|September 16, 2009
Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of AgingPhillip M Pierorazio, Luigi Ferrucci, Anna Kettermann, et al.
Urology|January 4, 2011
Distribution of PSA velocity by total PSA levels: data from the Baltimore Longitudinal Study of AgingStacy Loeb, H Ballentine Carter, Edward M Schaeffer, et al.
The Journal of Urology|August 18, 2009
Prostate volume changes over time: results from the Baltimore Longitudinal Study of AgingStacy Loeb, Anna Kettermann, H Ballentine Carter, et al.
Therapeutic Innovation & Regulatory Science|November 7, 2025
Navigating the Future: Considerations for use of Continuous Glucose Monitoring in Diabetes TrialsAnna Kettermann, Gauri Dandi, Jennifer Clark, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Methods in Molecular Biology (Clifton, N.J.)|April 19, 2022
Informatics in Medical Product Regulation: The Right Drug at the Right Dose for the Right PatientEileen Navarro Almario, Anna Kettermann, Vaishali Popat
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 9, 2014
Biomarkers of exposure among U.S. cigar smokers: an analysis of 1999-2012 National Health and Nutrition Examination Survey (NHANES) dataJiping Chen, Anna Kettermann, Brian L Rostron, et al.
Pharmaceutical Statistics|October 30, 2024
Optimizing Sample Size Determinations for Phase 3 Clinical Trials in Type 2 DiabetesAlexander C Cambon, James Travis, Liping Sun, et al.
Urology|November 10, 2007
Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curabilityH Ballentine Carter, Anna Kettermann, Luigi Ferrucci, et al.
European Urology|November 4, 2009
The Optimal Application of Prostate-Specific Antigen (PSA) Velocity to Predict High-Risk DiseaseStacy Loeb, Anna Kettermann, Luigi Ferrucci, et al.
European Urology|July 11, 2008
PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of AgingStacy Loeb, Anna Kettermann, Luigi Ferrucci, et al.
BJU International|September 16, 2009
Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of AgingPhillip M Pierorazio, Luigi Ferrucci, Anna Kettermann, et al.
Urology|January 4, 2011
Distribution of PSA velocity by total PSA levels: data from the Baltimore Longitudinal Study of AgingStacy Loeb, H Ballentine Carter, Edward M Schaeffer, et al.
The Journal of Urology|August 18, 2009
Prostate volume changes over time: results from the Baltimore Longitudinal Study of AgingStacy Loeb, Anna Kettermann, H Ballentine Carter, et al.
Therapeutic Innovation & Regulatory Science|November 7, 2025
Navigating the Future: Considerations for use of Continuous Glucose Monitoring in Diabetes TrialsAnna Kettermann, Gauri Dandi, Jennifer Clark, et al.
Pageof 3